The role of Orexin-A levels in epileptic seizure. (24th August 2020)

• Record Type: Journal Article
• Authors: Çikriklar, Halil Ibrahim; Kotan, Dilcan; Yücel, Murat; Ceylan, Mustafa; Çiftçi, Gönül G.; Bayraktutan, Ömer F.; Çiftçi, Ihsan H.
• Is Part Of: Neuroscience letters. Volume 734(2020)
• Publication Date: 2020-08-24
• Subjects: ES Epileptic seizures -- PNES Psychogenic Non-Epileptic -- EEG Seizures Electroencephalography -- BMI Body Mass Index -- DSM-4 Diagnostic and Statistical Manual of Mental Disorders-4 -- ANOVA Analysis of variance -- SD Standard deviation -- OX1R Orexin receptor 1 -- OX2R Orexin receptor 2; Orexin-A -- Epilepsy -- Pseudoseizures; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2020.135097
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Epileptic seizures are often confused with psychogenic non-epileptic seizures. True diagnoses often come late in psychogenic non-epileptic seizures patients. Delay in diagnostic procedures can cause patients to unnecessarily use many antiepileptic drugs Therefore, it is important to establish the differential diagnosis of epilepsy and non-epileptic seizures patients in the early period. Blood orexin levels may be an effective biomarker in the differential diagnosis of epileptic seizures and non-epileptic seizures patients. Abstract: Background: The aim of this study is to determine the usefulness of Orexin-A levels in differentiating between epileptic seizures and psychogenic non-epileptic seizures in patients presenting to the emergency service with epileptic seizure-type symptoms. Methods: A total of 80 individuals were included in this study, including 59 who presented to the emergency service within the first four hours of having been diagnosed with generalized tonic-clonic seizures (39 with epileptic seizures (ES) and 20 with pseudoseizures (PNES) and 21 controls. Orexin-A levels were measured in venous blood samples. Results: The mean Orexin-A levels were 5.16 ng/mL in the control group, 7.17 ng/mL in the PNES group, and 11.08 ng/mL in the ES group (Table 1). The mean Orexin-A level of the ES group was significantly different from both the control group and the PNES group (Table 1, p < 0.001); the difference between the control group and the PNES group was not significant (p > 0.05). Conclusions: Results of this study suggest that blood Orexin-A may be an effective biomarker in the differential diagnosis of epileptic seizures/psychogenic non-epileptic seizures in patients presenting to the emergency service with an epileptic seizure-type clinical picture.